{"doi":"10.1016/s2152-2650(23)00686-9","title":"POSTER: HL-642 Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?","abstract":null,"journal":"Clinical Lymphoma Myeloma and Leukemia","year":2023,"id":622716,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1609124,"name":"Joel Brothers","orcid":null,"position":1,"is_corresponding":false},{"id":1609125,"name":"Hamid Mirshahidi","orcid":null,"position":2,"is_corresponding":false},{"id":1609126,"name":"Mojtaba Akhtari","orcid":null,"position":3,"is_corresponding":false},{"id":1609123,"name":"Ravand Samaeekia","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"POSTER: HL-642 Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?","abstract":null,"is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W4386270898","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.28708447,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S2152265023006869?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2152265023006869?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/s2152-2650(23)00686-9","host_type":"journal"}],"fields_of_study":["Lymphoma Diagnosis and Treatment","Lung Cancer Treatments and Mutations","HER2/EGFR in Cancer Research"],"mesh_terms":[],"keywords":["Brentuximab vedotin","Hodgkin lymphoma","Interim","Medicine","Predictive value","Oncology","Medical physics","Internal medicine","Lymphoma","Nuclear medicine","Political science"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T20:46:26.171121Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}